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AbstrAct:
Recent studies indicate the importance of the ubiquitin ligase Siah2 in control of more 
aggressive prostate tumors – namely, neuroendocrine (NE) prostate tumors and 
prostate adenocarcinoma (PCa) harboring neuroendocrine lesions. Siah2-dependent 
expression and activity of HIF-1α regulate its availability to form a transcriptional 
complex with FoxA2, resulting in expression of specific target genes, including Hes6, 
Sox9 and Jmjd1a, whose co-expression is sufficient for formation of NE tumors and NE 
lesions in PCa. These studies provide novel markers to diagnose and monitor formation 
of NE lesions and NE tumors. Furthermore, defining the regulatory axis consisting of 
Siah2 and HIF-1α/FoxA2 cooperation suggests novel therapeutic modalities to treat 
these most aggressive forms of prostate cancer. Here we review current understanding 
of Siah role in control of hypoxia and prostate tumor development and highlight 
potential approaches for targeting components along Siah-regulated pathways.
the e3 ubiquitin ligAse siAh And 
its role in hypoxiA
Siah  is  a  RING  finger  E3  ubiquitin  ligase  that 
mediates  ubiquitination  and  degradation  of  substrates 
important in stress-activated signaling pathways [1, 2]. 
In  humans,  Siah  has  two  isoforms,  Siah1  and  Siah2, 
which usually target similar substrates. Siah consists of 
an N-terminal RING finger domain, a central cysteine-
rich domain and a C-terminal substrate-binding domain 
[3]. The  important  role  played  by  Siah  in  progression 
of multiple types of cancer, including lung, pancreatic, 
breast, prostate and melanoma, is evidenced by inhibition 
of  these  tumors  in  experimental  models  following 
attenuation of Siah activity [4-8]. 
HIF,  the  master  regulator  of  hypoxia  responses, 
controls diverse transcriptional programs under hypoxic 
conditions.  HIF  consists  of  a  heterodimer  between 
α-subunit (HIF-1α or HIF-2α) and β-subunit (HIF-1β). 
HIF-α levels are regulated by PHD (prolyl-hydroxylase)-
mediated  hydroxylation  of  two  proline  residues  that 
leads to VHL-dependent degradation. In addition HIF-α 
activities  are  regulated  by  FIH  (factor  inhibiting  HIF-
1α)-mediated  asparagine  hydroxylation  that  inhibits 
HIF  transcriptional  activity  by  disrupting  p300/CBP 
binding. Siah can elicit ubiquitination and degradation of 
PHD1/3 and FIH, thus stabilizing HIF-α and promoting 
its transcriptional activity [9, 10]. In addition, Siah has 
been shown to regulate the stability of HIPK2 [11, 12], a 
transcriptional repressor of the HIF-1α gene [13]. Thus, 
via  three  independent  pathways,  Siah  contributes  to 
HIF-α transcription, stability and activity. Consistently, 
cancer cells lacking Siah or expressing a Siah inhibitory 
peptide exhibit reduced levels and activity of HIF-α [7, 
8]. 
siAh in prostAte cAncer 
development And progression 
Prostate cancers are the most common malignancy 
in American men [14]. Hence, understanding mechanism 
underlying the development and progression of prostate 
cancers offers possible means for monitoring and therapy. 
Our  recent  study  demonstrates  the  importance  of  the 
Siah-HIF axis in development of prostate NE tumors and 
NE lesions in human prostate adenocarcinomas, which 
are among the more aggressive prostate tumors. Although 
prostate NE carcinomas are rare (< 5%), over 30% of 
human  prostate  adenocarcinomas  show  expression  of 
NE markers (e.g. NSE, chromogranin), often referred to Oncotarget 2010; 1:  379 - 385 380 www.impactjournals.com/oncotarget
as NE differentiation (NED) or the NE phenotype. NED 
of prostate cancers is associated with tumor progression, 
resistance  to  therapy  (such  as  androgen-deprivation 
therapy, radiotherapy, chemotherapy), and poor prognosis 
[15-18]. 
To  evaluate  a  potential  role  for  Siah  in  prostate 
tumor progression, we crossed Siah-deficient (Siah2-/- or 
Siah1a+/-::Siah2-/-) mice with the TRAMP mouse model. 
Prostate-specific  expression  of  SV40  T  antigen  in  the 
TRAMP mice leads to formation of two major types of 
lesions: prostate NE carcinoma and atypical hyperplasia 
(AH).  Siah-deficiency  significantly  reduced  formation 
of prostate NE carcinoma in TRAMP mice, while AH 
lesions  were  less  affected.  Siah-deficient  TRAMP  NE 
tumors  showed  reduced  HIF-1α  levels,  decreased  cell 
proliferation, increased cell death, but no apparent effect 
on vascular density. To confirm that impaired NE tumor 
formation is due to Siah’s effect on HIF, we transfected 
TRAMP cells with a Siah inhibitory peptide and observed 
reduced  HIF-1α  levels  and  inhibited  tumor  formation 
in nude mice. Conversely, forced re-expression of HIF-
1α in TRAMP cells expressing Siah inhibitory peptide 
partially  restored  these  cells’  ability  to  form  xenograft 
tumors, indicating that Siah regulation of HIF is essential 
for development of NE prostate tumors in the TRAMP 
model. Consistent with our study, AhR (aryl hydrocarbon 
receptor)-null TRAMP mice showed increased formation 
of  NE  carcinoma  but  not  of  AH  [19].  Since  HIF-1β 
dimerizes with both AhR and HIF-1α, lack of AhR may 
promote the formation of HIF-1α/HIF-1β dimers, thereby 
enhancing HIF activity and formation of NE carcinoma 
[20]. These  observations  underscore  the  importance  of 
HIF in the development of prostate NE carcinoma in the 
TRAMP model. 
The finding that NE tumors can no longer develop in 
the absence of Siah, combined with observation of reduced 
HIF-1α expression, led us to explore the possibility that 
HIF-1α  activity  is  required  for  the  formation  of  NE 
phenotypes. In addition to HIF-1β, HIF-α can also interact 
with other transcription factors such as β-catenin, Notch, 
c-Myc [21-24]. Thus, we tested the possibility that HIF 
may  elicit  a  tissue-specific  transcriptional  program  by 
interacting with factors expressed in NE tumors. Among 
transcription factors that are important for the formation 
of NE tumors in the TRAMP model is FoxA2 [25], a 
member of the Fork-head family of transcription factors 
consisting of FoxA1, FoxA2 and FoxA3 [26]. Although 
FoxA1 is expressed in both NE tumors and AH, FoxA2 
is only expressed in NE tumors in the TRAMP or LADY 
model [25, 27]. Using an HRE-luciferase assay that serves 
as a marker for HIF activity, we discovered FoxA2/HIF 
transcriptional  synergy  [7].  Notably,  FoxA2  interacted 
with HIF-1α via the N-terminal domains of each protein, 
promoting recruitment of p300 to specific HIF target genes 
and activating transcription. Consistent with the possibility 
that p300 can be recruited by specific HIF transcriptional 
program to induce a select set of proteins is the reports 
that MEFs isolated from mice harboring a mutant form of 
p300/CPB, which cannot interact with HIF-α, or MEFs 
derived from FIH KO mice showed impaired expression 
of only a subset of HIF target genes under hypoxia [28, 
29],  supporting  the  notion  that  p300/CBP  is  required 
for expression of specific HIF target genes. Cooperation 
between  FoxA2  and  HIF-1α  resulted  in  transcriptional 
activity that was substantially greater than that seen by HIF 
alone. Microarray analyses identified approximately 40 
genes (such as, Hes6, Sox9, Jmjd1a, and Plod2) that were 
co-regulated by HIF and FoxA2 in TRAMP cells, pointing 
to a specific transcriptional program that is regulated by 
this cooperation. Notably, some of the proteins that are 
regulated  by  HIF-1α-FoxA2  cooperation  were  reported 
to be HIF targets. In addition, FOXA binding sites have 
been found in some of the genes co-regulated by HIF and 
FoxA2  [7],  providing  additional  explanation  for  HIF/
FoxA2 synergy on specific HIF targets. 
Following  the  identification  of  HIF/FoxA2  target 
genes, we assessed their importance in development of 
prostate  NE  tumors.  In  these  studies  we  have  focused 
on assessing three genes: Hes6, Sox9 and Jmjd1a, which 
were  implicated  in  prostate  tumors,  and  were  shown 
(by us and others) to be regulated by HIF. To this end, 
TRAMP cells were engineered to express Siah-inhibitory 
peptide or FoxA2 shRNA. These modified cells showed 
reduced tumor-forming capacity in an orthotopic prostate 
tumor  model.  Significantly,  co-expression  of  Hes6, 
Sox9 and Jmjd1a partially rescued tumorigenic capacity 
in  the  presence  of  Siah-inhibitory  peptide,  confirming 
the  significance  of  the  pathway  in  prostate  NE  tumor 
development.  Notably,  re-expression  of  Hes6,  Sox  9 
or  Jmjd1a  individually  was  not  sufficient  to  rescue 
tumorigenesis in TRAMP cells in which either HIF or 
FOXA2  was  inhibited,  indicating  that  multiple  genes 
regulated  by  HIF/FoxA2  are  required  for  development 
of prostate NE tumors. We expect that co-expression of 
additional genes identified to be regulated by the HIF/
FoxA2 program will increase the rescue of these tumors.
siAh controls the formAtion of 
ne lesions in AdenocArcinomA of 
the prostAte.
The  specific  transcriptional  program  mediated  by 
HIF and FoxA2 also plays a key role in development of 
NE lesions (aka NED or NE phenotype) in human prostate 
adenocarcinoma. As a model to study NE phenotype in 
vitro we used the human prostate adenocarcinoma cell 
line  CWR22Rv1.  Notably,  when  maintained  under 
hypoxia  for  few  days  these  cells  show  upregulation 
of  the  NE  marker  NSE  and  protrusion  of  neurite-like 
structures  [7].  Correspondingly,  orthotopic  prostate 
tumors formed in mice by these human PCa cells exhibit 
high NSE levels in necrotic regions, which are known to Oncotarget 2010; 1:  379 - 385 381 www.impactjournals.com/oncotarget
be highly hypoxic. Thus, hypoxia appears to be important 
for prostate cancer NE phenotypes in vitro and in vivo. 
The in vitro NE phenotype of the CWR22Rv1 cells was 
Siah/HIF  and  FoxA2  dependent  and  could  be  rescued 
upon co-expression of the Hes6, Sox9 and Jmjd1a genes. 
Orthotopic  injection  of  CWR22Rv1  cells  expressing 
Siah-inhibitory  peptide  or  FoxA2  shRNA  did  not  alter 
their ability to develop tumors but rather abolished their 
propensity  to  metastasize  and  inhibited  the  appearance 
of  NE  phenotypes.  Co-expression  of  Hes6,  Sox9  and 
Jmjd1a was sufficient to rescue metastasis, indicating the 
importance of the NE phenotype the metastatic capacity 
of CWR22Rv1 cells. Consistent with these observations, 
immunohistochemistry  staining  of  a  prostate  cancer 
TMA and analysis of a microarray data revealed higher 
levels of Siah2, FoxA2, Hes6, Sox9, Jmjd1a and NSE in 
high-grade human PCa (Gleason score 4 and 5) and in 
metastatic prostate cancers [7]. These findings underscore 
the importance of the Siah2/HIF/FoxA2 axis in PCa NE 
phenotype, tumor progression and metastasis. 
Among other PCa cells that exhibit NED in culture 
are LNCaP cells. Although diverse stimuli, such as IL-6, 
radiation, or androgen deprivation, can induce NED in 
cultured  LNCaP  cells  [30-32],  androgen  deprivation  is 
the main inducer of NED in the mouse model [33-36]. 
Importantly, the incidence of NED is elevated in prostate 
cancer patients after androgen deprivation therapy [37]. 
Androgen deprivation causes damage of blood vessels in 
the prostate or prostate tumors with a consequent increase 
in hypoxia [38-40], which may contribute to the NED of 
prostate cancers. This possibility is consistent with our 
observation that NED occurs primarily in more hypoxic 
regions. 
Recent evidence indicates the presence of a small 
population of self-renewing and multipotent cells within 
solid tumors, termed cancer stem cells (CSCs) or tumor-
initiating cells [41]. These cells share many features with 
somatic and embryonic stem (ES) cells and are believed 
to drive tumor progression, metastasis and resistance to 
therapy. NED lesions of prostate cancers have been shown 
to express the stem cell marker Oct4A and the CSC marker 
CD44 [42, 43], implying that the NED lesions may harbor 
prostate cancer stem cells. In the TRAMP model, prostate 
NE tumors are believed to be derived from prostate stem 
cells in the mouse proximal prostate gland [25, 44]. The 
importance of Siah/HIF/FoxA2 axis in the formation of 
TRAMP NE tumor and NED of human prostate cancers 
suggests this signaling pathway may play a key role in the 
prostate stem cell function. 
Siah controls cooperation between HIF1α-FoxA2 in 
prostate tumor development and progression
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Figure 1 - Siah2 controls the HIF-1α levels in the hypoxic condition, allowing the availability of HIF-1α for interaction 
with the NE-specific transcription factor FoxA2, which is expressed in prostate EN tumor or the NE lesions of PCa. FoxA2/
HIF-1α interaction together with the recruitment of p300/CPB promotes the transcription of select HIF targets such as Hes6, Sox9, Jmjd1a and 
Plod2. The selective transcriptional program elicited by HIF/FoxA2 is required for the development of prostate NE tumors and formation of 
NED lesions in the PCa. Arrows point to components in this pathway that can be used for diagnosis and therapeutic targeting.Oncotarget 2010; 1:  379 - 385 382 www.impactjournals.com/oncotarget
possible clinicAl relevAnce
A. diagnostics
Based  on  our  identification  of  novel  proteins 
associated with the NE lesions and NE prostate tumors we 
assessed expression of Hes6 and Sox9 in tissue specimens. 
These  studies,  performed  by  IHC,  demonstrated  the 
ability  to  detect  NE  lesions  in  the  high-grade  prostate 
cancers. Given the difficulty of detecting NE lesions, the 
availability of new markers should promote development 
of additional antibodies and improved methods to detect 
these lesions, which are associated with poor prognosis. 
The ability to better define NE tumors and lesions at early 
disease stages should also impact treatment options and 
provide tools necessary to assess treatment efficacy. The 
availability of novel NED markers should also promote 
research into different types of NED (i.e., staining of the 
NE markers in single cells, cell clusters, or diffuse areas 
within  PCa)  and  facilitate  characterization  of  possible 
prostate CSCs within these lesions. 
B. Therapeutic Strategies 
As shown in Fig 1, the findings that Siah controls levels 
and activity of HIF-1α, which cooperates transcriptionally 
with  FoxA2  to  promote  NE  tumor  development  or 
formation of NED of human prostate cancers, provide a 
rationale for targeting the Siah/HIF/FoxA2 axis as a new 
therapeutic modality. Such an approach is supported by the 
following: (1) the presence of NED in PCa is associated 
with resistance to current therapies, including androgen 
deprivation therapy, radiotherapy and chemotherapy; and 
(2)  androgen  deprivation  therapy  or  radiotherapy  may 
induce NED of prostate cancers. Therefore, targeting the 
Siah/HIF/FoxA2 axis should inhibit the NE phenotype, 
sensitizing tumors to traditional prostate cancer therapy. 
Three components in the newly discovered pathway 
could  be  targeted  as  potential  therapies.  Of  the  three, 
Siah is likely the best candidate, since its loss abolishes 
formation  of  TRAMP  NE  tumors  and  restoring  HIF 
expression in such tumor cells only partially (30%) rescues 
formation of NE tumors. Notably, FoxA2 inhibition is less 
effective in attenuating NE tumor formation. As a RING 
finger E3 ubiquitin ligase Siah could be targeted in several 
ways. The least favorable is targeting its RING domain, 
given  its  similarity  with  the  RING  domain  present  in 
other E3 ligases. A Siah domain that would allow more 
specific  inhibition  is  the  substrate-binding  groove, 
which is required for binding with adaptors or substrates 
containing a peptide motif RPVAxVxPxxR, that mediates 
the interaction of Siah protein with a range of protein 
partners [45, 46]. A high-affinity interaction with a peptide 
from the cytoskeletal protein plectin-1 (residues 95–117) 
was identified with an apparent Kd of about 29 nM [45]. 
Given availability of structural data concerning the Siah2-
adaptor binding complex, and given the available crystal 
structure  of  Siah2  one  can  envision  use  of  structure-
based  design  of  peptides  and  peptide-mimetics  that 
selectively interfere with Siah2 association with selective 
substrates  or  adaptor  proteins  (Figure  2).  Structure-
based design combined with high throughput screening 
may allow identification of small molecules to block the 
Siah  substrate-binding  domain  (SBD).  Supporting  this 
approach is the observation that a 22 aa Siah inhibitory 
peptide can bind to the Siah SBD and reduce HIF levels 
under hypoxia [47]. A structure-based approach may be 
complemented  by  assessing  the  effect  of  inhibitors  on 
Siah2  self-ubiquitination,  a  property  inherent  to  RING 
finger E3 ligases. As a proof of principle, we recently 
established a Meso-Scale-based assay and, out of 2000 
Figure  2:  Molecular  models  representing  the  X-ray 
structure  of  SIAH1  in  complex  with  a  SIP  derived 
peptide  of  sequence  EKPAAVVAPITTG    (PDB-
id 2A25;). A  similar  docked  geometry  was  observed  in 
another –X-ray study with SIAH1 in complex with a 24 amino 
acids  Phyllopod  peptide  (PDB-ID  2AN6).  Top  panel:  ribbon 
representation of SIAH1 yellow, β-strands; cyan, loop regions, 
magenta, α-helical regions; the SIP peptide completes a β-strand 
and it is depicted in red. Bottom panel; SIAH-SIP complex is 
displayed in the same orientation as in the top panel, but SIAH1 
is shown as a surface representation, color coded according to a 
molecular lipophilicity potential (brown more lipophilic; green, 
neutral; blue, less lipophilic). The peptide is shown as a ball-and-
stick representation. The figure was prepared with MOLCAD as 
implemented in Sybyl (Tripos, St.Louis).  Oncotarget 2010; 1:  379 - 385 383 www.impactjournals.com/oncotarget
compounds,  identified  Menadione  as  a  Siah2  inhibitor. 
Menadione  treatment  inhibited  HIF  levels  in  cultured 
cells,  increased  expression  of  direct  Siah2  targets,  and 
inhibited formation of melanoma xenografts [48]. Given 
that  inhibition  of  Siah2  provides  an  unprecedented 
opportunity for the discovery of novel anti-cancer agents 
we believe that further drug discovery efforts are justified. 
Several inhibitors directed against HIF have been 
recently developed [49-51]. It is of importance to assess 
their  effects  in  prostate  tumor  models,  including  those 
used in our recent studies. A more specific target emerging 
from our studies, however, is the HIF/FoxA2 structural 
interface. The crystal structure of this complex or domain 
should  provide  information  required  to  develop  highly 
specific inhibitors. Although these inhibitors may not be 
as potent as HIF or Siah inhibitors, they could be more 
specific to the NE phenotype. Notably, targeting protein-
protein  interaction  has  been  a  less  favorable  approach 
for  drug  design;  thus  development  of  more  advanced 
technologies is required to make this task more feasible. 
Structure-based  approaches  will  likely  dominate  the 
search for Siah and HIF/FoxA2 inhibitors. 
Inhibiting  specific  HIF-FoxA2  targets  is  also  a 
possibility.  Some  of  these  proteins  identified  in  our 
studies,  such  as  Jmjd1a  and  Plod2,  exhibit  intrinsic 
enzymatic  activity.  Studies  are  underway  to  assess  the 
consequence of their selective inhibition on NE tumors 
and NED lesions in culture and in vivo. Of consideration 
is the notion that unless inhibitors are targeted specifically 
to  NE  cells,  blocking  these  enzymes  might  promote 
pleiotropic effects. 
Targeting components along the newly discovered 
Siah/HIF/FoxA2  axis,  which  functions  in  formation 
of  prostate  cancer  NE  phenotypes  and  is  potentially 
associated  with  the  prostate  cancer  stem  cells,  should 
complement current diagnosis and therapies for prostate 
cancer patients whose tumors harbor NE markers. 
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